ArticleBMC cancer2020

EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors.

Anne C Chiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.